Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:BLTE NASDAQ:CGON NASDAQ:COGT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$9.45-0.1%$9.43$7.48▼$18.57$1.42B1.321.94 million shs1.44 million shsBLTEBelite Bio$137.30$158.61$56.10▼$200.00$5.49B-1.19121,893 shs107,735 shsCGONCG Oncology$64.25$67.26$23.65▼$75.50$5.67B0.41849,252 shs652,815 shsCOGTCogent Biosciences$32.67$35.29$4.75▼$43.73$5.58B0.371.55 million shs1.97 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven0.00%+11.17%-4.25%-20.19%-39.72%BLTEBelite Bio0.00%-3.92%-14.86%-26.24%+125.08%CGONCG Oncology0.00%+2.10%-6.45%+10.13%+152.56%COGTCogent Biosciences0.00%+4.18%-11.25%-16.62%+577.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$9.45-0.1%$9.43$7.48▼$18.57$1.42B1.321.94 million shs1.44 million shsBLTEBelite Bio$137.30$158.61$56.10▼$200.00$5.49B-1.19121,893 shs107,735 shsCGONCG Oncology$64.25$67.26$23.65▼$75.50$5.67B0.41849,252 shs652,815 shsCOGTCogent Biosciences$32.67$35.29$4.75▼$43.73$5.58B0.371.55 million shs1.97 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven0.00%+11.17%-4.25%-20.19%-39.72%BLTEBelite Bio0.00%-3.92%-14.86%-26.24%+125.08%CGONCG Oncology0.00%+2.10%-6.45%+10.13%+152.56%COGTCogent Biosciences0.00%+4.18%-11.25%-16.62%+577.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 2.71Moderate Buy$22.27135.75% UpsideBLTEBelite Bio 2.63Moderate Buy$203.8048.43% UpsideCGONCG Oncology 2.71Moderate Buy$81.7327.20% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7333.85% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, CGON, COGT, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BLTEBelite Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$217.005/22/2026BLTEBelite Bio BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.005/19/2026CGONCG Oncology Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026CGONCG Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.005/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/13/2026BHVNBiohaven Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.005/11/2026CGONCG Oncology JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$91.00 ➝ $96.005/11/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$79.00 ➝ $81.005/11/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $77.005/11/2026CGONCG Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $80.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$0.86 per shareN/ABLTEBelite BioN/AN/AN/AN/A$19.91 per shareN/ACGONCG Oncology$4.04M1,402.69N/AN/A$12.38 per share5.19COGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)BLTEBelite Bio-$77.61M-$2.53N/A114.42N/AN/A-13.14%-12.88%8/10/2026 (Estimated)CGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)Latest BHVN, CGON, COGT, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A3/2/2026Q4 2025BHVNBiohaven-$1.22-$1.21+$0.01-$1.21$3.86 millionN/A3/2/2026Q4 2025BLTEBelite Bio-$0.56-$0.38+$0.18-$0.70N/AN/A2/27/2026Q4 2025CGONCG Oncology-$0.61-$0.51+$0.10-$0.51N/A$2.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.877.417.41BLTEBelite BioN/A33.7150.02CGONCG OncologyN/A31.3031.25COGTCogent Biosciences0.4115.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%BLTEBelite Bio0.53%CGONCG Oncology26.56%COGTCogent BiosciencesN/AInsider OwnershipCompanyInsider OwnershipBHVNBiohaven13.80%BLTEBelite Bio13.29%CGONCG Oncology4.80%COGTCogent Biosciences7.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239150.56 million129.78 millionOptionableBLTEBelite Bio1039.97 million34.65 millionNot OptionableCGONCG Oncology6188.20 million83.97 millionOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableBHVN, CGON, COGT, and BLTE HeadlinesRecent News About These CompaniesCogent Biosciences Announces Presentations of Pivotal APEX Trial Data and JAK2 V617F Program at EHA Congress 2026May 12, 2026 | quiverquant.comQCogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 CongressMay 12, 2026 | globenewswire.comPier Capital LLC Buys Shares of 46,260 Cogent Biosciences, Inc. $COGTMay 8, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Orthofix Medical (OFIX), BioNTech SE (BNTX) and Cogent Biosciences (COGT)May 8, 2026 | theglobeandmail.comCogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory ProgressMay 8, 2026 | finance.yahoo.comCogent Biosciences, Inc. $COGT Shares Purchased by Vanguard Group Inc.May 7, 2026 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Releases Earnings ResultsMay 5, 2026 | marketbeat.comCogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial ResultsMay 5, 2026 | finanznachrichten.deCogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comPictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGTMay 4, 2026 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by AnalystsMay 4, 2026 | marketbeat.comTeachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGTApril 29, 2026 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short InterestApril 28, 2026 | marketbeat.comCogent Biosciences (COGT) Expected to Announce Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingApril 21, 2026 | globenewswire.comCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026April 17, 2026 | globenewswire.comDoes Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)?April 12, 2026 | finance.yahoo.comCogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stockApril 8, 2026 | msn.comCogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'April 2, 2026 | seekingalpha.comCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)April 1, 2026 | globenewswire.comCogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analystsMarch 30, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, CGON, COGT, and BLTE Company DescriptionsBiohaven NYSE:BHVN$9.44 -0.01 (-0.05%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$9.38 -0.06 (-0.69%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Belite Bio NASDAQ:BLTE$137.30 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$137.36 +0.06 (+0.04%) As of 05/22/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.CG Oncology NASDAQ:CGON$64.25 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$64.25 0.00 (0.00%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Cogent Biosciences NASDAQ:COGT$32.67 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$32.66 -0.02 (-0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
